^
Association details:
Biomarker:IDH1 mutation + TMB-L
Cancer:Glioma
Drug:Opdivo (nivolumab) (PD1 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Phase II trial evaluating nivolumab in patients with recurrent IDH-mutant gliomas with and without hypermutation phenotype.

Published date:
05/25/2023
Excerpt:
As of May 2022, 17 patients were enrolled to NHMP cohort and 15 were treated (TMB˂5 mut/Mb)...Six out of 15 (40%) patients were progression free at 6 months...Nivolumab is well tolerated and has demonstrated efficacy in a cohort of patients with recurrent IDH-mutant gliomas with low TMB.
DOI:
10.1200/JCO.2023.41.16_suppl.e14043
Trial ID: